Abstract:We read with great interest the recent publication by Xie et al., addressing the issue of next-generation sequencing (NGS) for diagnosis of severe pneumonia in China.1Xie Y Du J Jin W et al.Next generation sequencing for diagnosis of severe pneumonia: China, 2010-2018.J Infect. 2019; 78: 158-169Abstract Full Text Full Text PDF PubMed Scopus (83) Google Scholar They suggested that NGS might lead to more rapid and accurate diagnosis with better clinical prognosis than conventional detection methods in severe pneumonia in ICU. NGS is a novel method to DNA/RNA sequencing. Due to its high-throughput capacity and fast turnover time, NGS technology has been widely applied to the field of medical microbiology in recent years. NGS has been reported in the application for pathogen detection from blood, cerebrospinal fluid, tissue and intraoperative samples.2Guan H Shen A Lv X et al.Detection of virus in CSF from the cases with meningoencephalitis by next-generation sequencing.J Neurovirol. 2016; 22: 240-245Crossref PubMed Scopus (103) Google Scholar, 3Long Y Zhang Y Gong Y et al.Diagnosis of sepsis with cell-free DNA by next-generation sequencing technology in ICU patients.Arch Med Res. 2016; 47: 365-371Crossref PubMed Scopus (175) Google Scholar, 4Ai JW Li Y Cheng Q et al.Diagnosis of local hepatic tuberculosis through next-generation sequencing: smarter, faster and better.Clin Res Hepatol Gastroenterol. 2018; 42: 178-181Crossref PubMed Scopus (32) Google Scholar However, no studies have been reported from bronchoalveolar lavage fluid (BALF) samples in community-acquired pneumonia (CAP) patients with immunosuppression. Compared with the immunocompetent host, CAP can be potentially fatal and present significant challenges in immunocompromised host (ICH). In addition to common pathogens, some unusual organisms can cause severe infection in ICH. Besides, multiple concurrent infections are also common in ICH.5Godbole G Gant V Respiratory tract infections in the immunocompromised.Curr Opin Pulm Med. 2013; 19: 244-250Crossref PubMed Scopus (31) Google Scholar These characteristics pose a severe challenge to establish a specific diagnosis to guide therapy. A diagnostic tool should be pursued aggressively for favorable outcomes in this population. We recently explored the utility of NGS of bronchoalveolar lavage on the diagnosis of pneumonia in immunocompromised patients. Thirteen immunocompromised patients with a diagnosis of communty-acquired pneumonia (CAP) were recruited from critical care department of Shanghai Ruijin Hospital. The diagnosis of CAP is based on the presence of select clinical features (e.g., cough, fever, sputum production, and pleuritic chest pain) and is supported by imaging of the lung, usually by chest radiography. Immunosuppression, defined as chemotherapy or neutropenia < 1000 µL during the past 28 days; treatment ≥ 20 mg corticosteroids daily for ≥ 14 days; human immunodeficiency virus infection; immunosuppressive therapy after organ or bone marrow transplantation; and active tuberculosis. Fiberoptic bronchoscopy was performed under local anesthesia with topical lidocaine for patients. BALF specimens using three aliquots of 20 mL of 0.9% saline were obtained. The first was discarded as recommended. The others were pooled and separated into two aliquots. One aliquot was sent to the microbiology lab for direct examination with Gram stain and culture. The other one was sent for DNA extraction and sequencing. Standard procedures (SP) of BALF microbiologic testing were performed in all patients, which included quantitative cultures for bacteria, mycobacteria and fungi. In addition, multiplex PCR for influenza A/B, parainfluenza 1/2/3/4, coronavirus OC43, coronavirus 229E/NL63, respiratory syncytial virus A/B, adenovirus, human metapneumovirus, human rhinovirus, enterovirus and Human bocavirus was performed on BALF and nasopharyngeal. CMV, EBV, HSV-I, and HSV-II serology for IgG and IgM antibodies were measured. Clinical characteristics including sex, age, APACHE II score at the time of diagnosis of CAP were demonstrated in Table 1. All patients were considered to be immunocompromised due to corticosteroids therapy or other immunosuppressive drugs.6Jensen AV Faurholt-Jepsen D Egelund GB et al.Undiagnosed diabetes mellitus in community-acquired pneumonia: a prospective cohort study.Clin Infect Dis. 2017; 65: 2091-2098Google ScholarTable 1Clinical characteristics of patients included.Characteristics13 patientsAge (years)52 (46.5–71)Female/male (n)5/8APACHEII score23 (19–30.5)Laboratory findings White blood cells (109 cells/L)8.7 (5.3–12.1) Lymphocytes (109 cells/L)0.4 (0.2–0.99) CRP (mg/L)46.6 (19.5–89) PCT (ng/ml)1.03 (0.22–4.75) CD3+T cell count (cells/ul)215 (141.5–564) CD3+T %63.6 (51.75–81.65) CD3+4+ T cell count (cells/ul)97 (59.5–181.5) CD3+4+ T %31.4 (17.1–39.45) CD3+8+ T cell count (cells/ul)89 (63.5–201.5) CD3+8+ T %24.9 (21–42.9)Radiologic findings Consolidation7 Interstitial/patchy involvement8Immunodeficiency Nephrotic syndrome3 Renal transplantation2 Sjogren Syndrome2 Adult onset Still's disease1 Dermatomyositis1 Rheumatic arthritis1 Systemic vasculitis1 Psoriasis1 Open table in a new tab SP identified pathogens in 6 patients (6/13), four of which were bacteria, one fungi and one virus detected by clinical respiratory viral PCR panels (Table 2). It is worth noting that two samples positive for Acinetobacter baumannii by SP were considered co-infected with PJP or CMV respectively by NGS. NGS detected pathogens in 12 patients (12/13) and one sample with non-infectious etiologies was confirmed by NGS (Table 2). Importantly, five PJP infections and one Aspergillus fumigatus infection were recognized by NGS. Moreover, among the six fungi-positive samples, CMV was also identified in three of them (two PJP and one Aspergillus fumigatus). Being relatively uncommon pathogens among the immunocompromised, PJP were identified in 5 cases and CMV in 4 cases by NGS. However, CMV serology for IgM were negative in these patients. No methenamine silver staining was performed in these cases, for the detecting item has not been carried out in our hospital. Overall, four bacteria, one fungus and one virus were detected by SP. By comparison, four bacteria, seven fungi and five viruses were identified by NGS (Table 2).Table 2Next-generation sequencing of BALF for the patients with pneumonia.Case numberPathogens identified by SPPathogens identified by NGSRaw ReadsSMRNGenomic coverage (%)1NonePneumocystis Jiroveci188318102.63Cytomegalovirus446.092NonePneumocystis Jiroveci218320602.85Cytomegalovirus16160.843Human BocavirusHuman Bocavirus2524434NoneAspergillus Fumigatus8486080.3Cytomegalovirus2583424833955Stenotrophomonas MaltophiliaStenotrophomonas Maltophilia86416153186Acinetobacter BaumanniiAcinetobacter Baumannii332224158.43Cytomegalovirus440.207Candida AlbicansCandida Albicans30280.038NonePneumocystis Jiroveci96950.159NoneHuman Simple Virus I26192254729510Acinetobacter BaumanniiAcinetobacter Baumannii11817471.43Pneumocystis Jiroveci397537912.3211NonePneumocystis Jiroveci1051030.0612Acinetobacter BaumanniiAcinetobacter Baumannii18686013948685.4413NoneNoneSMRN: strictly map reads number. Open table in a new tab SMRN: strictly map reads number. In terms of bacteria detection, NGS showed no significant advantages in this study. It is noteworthy that our study demonstrated NGS has a distinct advantage in the field of fungi and viral testing, especially PJP and CMV detection. The definitive PJP diagnosis usually requires demonstration of fungus in tissue, BALF, or induced sputum samples. Methenamine silver staining and PCR in BALF samples have good sensitivity and specificity and is an emerging modality for diagnosis in the correct clinical setting.7Rali P Veer M Gupta N et al.Opportunistic pulmonary infections in immunocompromised hosts.Crit Care Nurs Q. 2016; 39: 161-175Google Scholar, 8Kaplan JE Benson C Holmes KK et al.Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV medicine association of the infectious diseases society of America.MMWR Recomm Rep. 2009; 58 (quiz CE1-4): 1-207Google Scholar There are a few laboratory tests to detect CMV infection.7Rali P Veer M Gupta N et al.Opportunistic pulmonary infections in immunocompromised hosts.Crit Care Nurs Q. 2016; 39: 161-175Google Scholar Histopathologic analysis or viral culture from tissue, blood, urine, or respiratory specimens is less utilized because of poor sensitivity and longer time-consuming. CMV serology for IgG and IgM antibodies is another diagnostic tool but may be negative and inconclusive in immunocompromised hosts. The other methods such as PCR and pp65 antigenemia assays have not been carried out widely.7Rali P Veer M Gupta N et al.Opportunistic pulmonary infections in immunocompromised hosts.Crit Care Nurs Q. 2016; 39: 161-175Google Scholar,9Fishman JA Infection in solid-organ transplant recipients.N Engl J Med. 2007; 357: 2601-2614Crossref PubMed Scopus (1515) Google Scholar NGS technology showed its remarkable advantages in terms of opportunistic pathogens in patients with immunocompromised states. In recent years, clinicians have been increasingly aware of the problem of mixed infection in immunocompromised hosts.10Crotty MP Meyers S Hampton N et al.Epidemiology, co-infections, and outcomes of viral pneumonia in adults: an observational cohort study.Medicine. 2015; 94 (Baltimore): e2332Crossref PubMed Scopus (44) Google Scholar However, to diagnosis the co-occurrence of two commonly seen opportunistic infections is difficult in immunocompromised patients with lung infiltrates. It is worth noting the distinct advantage of NGS in concurrent detection of bacteria, fungi and viruses. In our study, standard procedures performed poorly in detecting mixed infections, whereas five cases with coinfection of bacteria, fungi or viruses were identified by NGS. This advantage may help clinicians more comprehensive evaluation of patients and make effective treatment. In conclusion, our study explored the application of NGS in the microbiologic diagnosis in CAP patients with immunosuppression. NGS technology showed its remarkable advantages in detecting opportunistic pathogens and mixed infection in those patients. The study protocol was approved by the Ruijin Hospital Ethics Committee, Shanghai Jiaotong University School of Medicine, China. Formal consent was obtained from the patient or the next of kin. This study was supported by the National Key R&D Program of China (2017YFC1309700, 2017YFC1309705), National Natural Science Foundation of China (81772040, 81770005, 81801885) and Shanghai Sailing Program (18YF1413800).

The Clinical Value of Metagenomic Next-Generation Sequencing in Pneumocystis jirovecii Pneumonia

Metagenomic Next-Generation Sequencing for Accurate Diagnosis of Pneumocystis jirovecii Pneumonia: A Comparative Study with Traditional Methods

Diagnostic Value of Metagenomic Next-Generation Sequencing for Multi-Pathogenic Pneumonia in HIV-Infected Patients.

Study on mNGS Technique in Diagnosing Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Patients

Application of Metagenomic Next-Generation Sequencing to Diagnose Pneumocystis Jirovecii Pneumonia in Kidney Transplantation Recipients

Diagnostic Value of Bronchoalveolar Lavage Fluid Metagenomic Next-Generation Sequencing in Pneumocystis jirovecii Pneumonia in Non-HIV Immunosuppressed Patients

Diagnostic values of BALF metagenomic next-generation sequencing, BALF real-time PCR and serum BDG for Pneumocystis jirovecii pneumonia in HIV-infected patients

Clinical features and diagnostic value of metagenomic next -generation sequencing in five cases of non-HIV related Pneumocystis jirovecii pneumonia in children

Lessons from Multiple Infections Such as Lymphoma Complicated with Pneumocystis Infection: A Case Report

Characteristics and Prognostic Factors of Non-HIV Immunocompromised Patients With Pneumocystis Pneumonia Diagnosed by Metagenomics Next-Generation Sequencing

Clinical Efficiency of Metagenomic Next-Generation Sequencing in Sputum for Pathogen Detection of Patients with Pneumonia According to Disease Severity and Host Immune Status

Clinical Impact of Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage in the Diagnosis and Management of Pneumonia A Multicenter Prospective Observational Study

Clinical Performance of BAL Metagenomic Next-Generation Sequence and Serum (1,3)-β-D-Glucan for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonisation

Diagnostic Value of Metagenomic Next-Generation Sequencing for Pneumonia in Immunocompromised Patients.

Next-generation Sequencing of the BALF in the Diagnosis of Community-Acquired Pneumonia in Immunocompromised Patients

Metagenomic Next-Generation Sequencing in Diagnosis of a Case of Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient and Literature Review

Co-Infection Pneumonia with Mycobacterium Abscessus and Pneumocystis Jiroveci in a Patient Without HIV Infection Diagnosed by Metagenomic Next-Generation Sequencing

Clinical Characteristics and Prognostic Predictors of Pneumocystis Jirovecii Pneumonia in Patients with and without Chronic Pulmonary Disease: A Retrospective Cohort Study

Clinical Evaluation Of A Metagenomics-Based Assay For Pneumonia Management

Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches

Pneumocystis Pneumonia and Rheumatic Disease: Diagnostic Potential of Circulating Microbial Cell-Free DNA Sequencing.